Abbvie Bioresearch Center

Pratt & Whitney is one of the world s leaders in the design, manufacture and service of aircraft engines, space propulsion systems and industrial gas turbines. Founded in 1925, the company s more than 38,500 employees support over 9,000 customers in nearly 150 countries throughout the world. It builds engines for front line fighters, including F-15 Eagle, F-16 Fighting Falcon, F-22 Raptor and F-35 Joint Strike Fighter. Pratt & Whitney offers fleet management and engine overhaul services to customers in the military sector. It has a public-private partnership with the USAF Oklahoma City Air Logistics Center. The company s industrial gas turbine business, Pratt & Whitney Power Systems (PWPS), provides power generation and mechanical solutions for the electric generation and oil and gas markets. Pratt & Whitney is a subsidiary of United Technologies Corporation, which serves the aerospace and commercial building industries worldwide.

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website